Quick Facts: Uses of Lutalyse

• Estrous Management: May be utilized to assist with the coordination of estrous timing in cycling cattle and mares.
• Reproductive Conditions: Is intended to assist in the management of chronic endometritis (pyometra) in cattle.
• Breeding Programs: May support fixed-time artificial insemination protocols in cattle to assist with reproductive efficiency.

---

Lutalyse (dinoprost tromethamine injection) is an agent approved for use in livestock and equines to support reproductive health management. It is utilized in cattle, swine, and mares with a functional corpus luteum to assist in regulating the timing of reproductive events.

In cattle, a primary use is to assist with the synchronization of estrus. This is intended to support efficient breeding programs. The medication may also be used to manage specific reproductive health challenges, including unobserved (silent) estrus in dairy cows and the treatment of pyometra (a chronic uterine condition). Additionally, it may be administered to induce abortion in non-lactating or feedlot cattle, and to support the induction of labor (parturition) in swine.

In mares, this product is utilized to manage and coordinate estrus timing. All applications must be performed under the guidance of a licensed veterinarian to ensure appropriate protocols are followed.

Regulatory References

1. FDA veterinary guidance for dinoprost tromethamine

The eligibility for the veterinary medicine Lutalyse (dinoprost tromethamine) is strictly defined by regulatory authorities based on the target species, their physiological status, and the presence of specific medical conditions.

Populations Allowed and Required Conditions

Lutalyse is approved for use in cattle, swine, and mares. For the treatment to be effective, the animal must possess a functional corpus luteum (CL), which establishes a minimum physiological requirement. Regulatory documents permit use in lactating cattle.

Absolute Contraindications

The product is strictly not for human use. It is formally contraindicated in animals suffering from acute or sub-acute disorders of the vascular system, gastro-intestinal tract, or respiratory system. Additionally, the medicine must not be administered to any pregnant animal unless the specific, desired outcome is the induction of abortion or parturition.

Restrictions for Human Handlers

Because the drug can be absorbed through the skin, the regulatory label imposes restrictions for human handlers. Women of childbearing age and individuals with asthma or other respiratory problems must exercise extreme caution when handling the product, as exposure may potentially cause miscarriage or bronchospasms.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dinoprost tromethamine (Lutalyse) primarily through restrictions based on pharmacodynamic effects and specific pre-existing physiological conditions.

Documented Pharmacodynamic Interactions

Interacting Substance Class	Interaction Type	Official Restriction	Outcome as Described in Label
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Pharmacodynamic Antagonism	Should not be administered concurrently	Potential to diminish the expected efficacy by inhibiting prostaglandin synthesis.
Other Oxytocic Agents (e.g., Oxytocin)	Pharmacodynamic Potentiation	Not recommended for concurrent use	May lead to an amplification of uterotonic effects (additive smooth muscle contraction).

No mandatory timing-based separation requirements are specified in the official regulatory prescribing information for co-administered agents. Furthermore, the regulatory labels do not contain specific information regarding pharmacokinetic, metabolic enzyme, or drug transporter-mediated interactions.

Condition-Based Interaction Constraint

Use of Lutalyse is formally contra-indicated in animals suffering from acute or sub-acute disorders of the vascular system, gastro-intestinal tract, or respiratory system. This restriction is due to the potential for the drug's inherent properties to interact negatively with these specific physiological states, as stated in official labeling.

Lutalyse contains dinoprost tromethamine, a synthetic analog of the naturally occurring lipid mediator Prostaglandin F2alpha (PGF2alpha). The drug exerts its effect by acting as a highly selective agonist of the Prostaglandin F2alpha receptor (PTGFR), a G-protein coupled receptor expressed on target cells, including those of the corpus luteum and myometrium.

Activation of PTGFR initiates specific intracellular signaling sequences, primarily involving the phosphatidylinositol-calcium second messenger system. In the ovary, this cascade triggers luteolysis, resulting in the structural and functional regression of the corpus luteum (CL). The degradation of the CL immediately halts progesterone synthesis, the primary endocrine consequence that subsequently shifts the hormonal environment toward the follicular phase.

Concurrently, PTGFR activation on myometrial smooth muscle cells induces uterine contractions. This direct pharmacodynamic effect mechanically alters the environment within the uterine lumen.

How to Use Lutalyse (Dinoprost Tromethamine)

Lutalyse is officially administered by injection, with the intramuscular (IM) route being the standard method for all approved species, including cattle, swine, and mares. The high-concentration formulation is also approved for subcutaneous (SC) injection in cattle. The medication is supplied as a sterile injectable solution at two concentrations: 5 mg dinoprost/mL or 12.5 mg dinoprost/mL (HighCon).

Standard Dosing and Frequency

Administration follows standardized, species-specific dosing schedules, which are defined by milligram amounts, not by weight (except for the general mare range). The drug's efficacy relies on the animal possessing a functional corpus luteum, typically present at least five days post-ovulation.

Target Species	Standard Single Dose	Frequency and Timing Constraint
Cattle	25 mg dinoprost	Single use, or two injections separated by a 10- to 12-day interval for synchronization.
Swine	10 mg dinoprost	Single use for parturition induction, restricted to within 3 days of the normal predicted farrowing date.
Mares	5 mg dinoprost	Single use for estrus control.

Procedural Administration Constraints

Official instructions require the use of aseptic technique during administration, including the use of sterile, single-use needles and proper disinfection of the vial stopper. A key procedural restriction, defined to reduce the risk of post-injection infection, specifies that the vial stopper should be entered no more than 20 times. The solution must never be administered intravenously (IV).

Research evidence / Overview of studies for Lutalyse

Evidence for Estrus Synchronization and Breeding Management (Cattle)

Research examined dinoprost tromethamine for its use in protocols designed to influence the timing of the reproductive cycle, such as those related to Fixed-Time Artificial Insemination (FTAI). These investigations typically take the form of pivotal, multi-site Randomized Clinical Trials (RCTs) and controlled field studies, which often compare outcomes against different hormone protocols or other similar drugs. The populations evaluated in these studies are cows and heifers confirmed to have a functional corpus luteum (a temporary reproductive structure that the drug targets).

The studies examined primary outcomes related to systemic or functional imbalance, such as the rate of decline of the progesterone ( P4) hormone levels, which was monitored in the reproductive structure. Findings describe patterns observed in the studies where treatment was associated with a measurable change in hormone levels and a defined pattern of breeding events.

---

Evidence for Therapeutic Use and Reproductive Timing

Dinoprost tromethamine was studied for the therapeutic management of uterine health issues in cattle, primarily pyometra (a chronic uterine condition). These investigations include controlled clinical field studies that examined outcomes related to systemic or functional imbalance, such as changes in the reproductive tract and clearance of fluid. Separately, the drug was evaluated in studies focusing on the planned induction of abortion in beef and replacement dairy heifers during the first half of pregnancy.

Research also examined the drug's use for scheduling reproductive events in other species. In swine, controlled field trials was studied for the induction of parturition (farrowing), with outcomes measured as the precise interval from treatment to the onset of farrowing. For mares, research explored the ability to stimulate estrus by causing luteolysis in animals with extended diestrus.

---

Research Gaps and Uncertainty

One key limitation is that most research involves using dinoprost tromethamine as part of a multi-component hormone protocol; therefore, comparative evidence is lacking to isolate the full effect of the drug when used without other hormone products in many settings. Furthermore, because follow-up durations were limited in many pivotal trials, there is limited information for long-term outcomes related to subsequent breeding cycles.

Key Studies & References

1. Dinoprost Tromethamine Injection Solution Label (Lutalyse): Official Monograph

Common questions about Lutalyse (FAQ)

Q: How quickly does Lutalyse cause luteolysis after injection?

A: Regulatory studies suggest that the drug's mechanism of action is intended to rapidly initiate the process of luteolysis, which is the breakdown of the corpus luteum (CL). This effect leads to a measurable change in progesterone hormone levels shortly after administration. The precise time until the functional change is complete can vary depending on the animal species and their individual reproductive stage.

Q: Can Lutalyse be used in pregnant animals?

A: According to official regulatory documents, the medication is generally advised against for use in pregnant animals. Exceptions are generally limited to specific veterinary protocols where the desired outcome is the induction of abortion or the induction of parturition (farrowing or calving) near the predicted date. Outside of these specific, intended uses, it is formally contraindicated.

Q: Is there a risk of allergic reaction to Lutalyse?

A: Official labeling reports serious adverse effects, such as potentially life-threatening localized bacterial infections following injection. The regulatory documents do not consistently emphasize common allergic reactions or hypersensitivity events within their mandatory warnings sections, but any adverse reaction should be reported to a veterinarian.

Q: What is the difference between the 5mg/mL and 12.5mg/mL Lutalyse concentrations?

A: Lutalyse is available as a sterile injectable solution in two concentrations: 5 mg dinoprost/mL and 12.5 mg dinoprost/mL (HighCon). Official product information indicates that the higher concentration is specifically approved for the subcutaneous (SC) route in cattle, while both concentrations are approved for the standard intramuscular (IM) route.

Q: How long after the first dose do I need to wait to re-treat cattle for synchronization?

A: Regulatory guidelines for estrus synchronization protocols describe that administration is often a single use. However, when two injections are used as part of a synchronization program in cattle, they are typically administered with an interval of 10 to 12 days between doses.

Q: Can I use Lutalyse to treat retained placenta in cattle?

A: The drug is officially approved for therapeutic use in cattle for reproductive conditions such as pyometra (a chronic uterine infection). The specific use for the treatment of retained placenta is not uniformly listed as an approved indication on the primary regulatory labels, meaning its use for this condition would fall outside the standard approved indications.

Official Storage and Disposal Requirements

Lutalyse (dinoprost tromethamine injection) must be stored under specific environmental conditions as outlined in regulatory labeling. The product requires storage at controlled room temperature, specifically maintained between 20 C and 25 C (68 F to 77 F). It is essential that the medicine is protected from freezing at all times.

Storage Constraint	Requirement
Temperature	20 C to 25 C (Controlled Room Temperature)
Stability	Use contents within 12 weeks of the first vial puncture
Protection	Protect from freezing; Keep out of the reach of children
Disposal	Must be carried out in accordance with local requirements

For child safety, the product must be kept out of the reach of children, as it is strictly Not for human use. Disposal of any unused product or waste materials must follow established local regulatory requirements.